Advances in Cancer Immunotherapy™️ Webinar: Clinical Updates from ASCO 2021 Webinar

When:  Oct 6, 2021 from 14:00 to 15:00 (ET)
On October 6, 2021 at 2:00 pm ET, join Evan J. Lipson, MD, and other leading experts in cancer immunotherapy as they discuss the latest and most exciting clinical updates emerging from ASCO 2021.

This FREE, CME-, CNE-, CPE- and MOC- certified webinar is a chance for clinical oncologists, registered nurses, nurse practitioners, advanced practice registered nurses, pharmacists, physician assistants, emergency physicians, allied health professionals, other patient care providers, students, and patient advocates, to learn about key clinical implications from select ASCO 2021 presentations.

This live webinar will also feature a dedicated question and answer session to address your questions about clinical applications of cancer immunotherapy. Don't miss this opportunity to continue learning about the expanding cancer immunotherapy field!

Featured presentations: 

  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. - Presenter: Ulka Vaishampayan, MD
  • First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA - Presenter: Jarushka Naidoo, MBBCH, MHS
  • Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. - Presenter: Matthew Frigault, MD, MSc
Webinar Faculty:
  • Moderator: Evan J. Lipson, MD  – Johns Hopkins University
  • Presenters:
    • Matthew Frigault, MD, MSc - Massachusetts General Hospital
    • Ulka Vaishampayan, MD – University of Michigan
    • Jarushka Naidoo, MBBCH, MHS – Beaumont RCSI Cancer Centre Dublin
Webinar Agenda:

  • 2:00-2:05 p.m. ET Overview: Welcome and Introductions
  • 2:05-2:45 p.m. ET Presentations
  • 2:45-2:55 p.m. ET Question and Answer Session
  • 2:55-3:00 p.m. ET Closing Remarks
Continuing Education Credit Information:
Continuing Education Credits are available for physicians, nurses, and pharmacists. To view full accreditation information, click here.

The 2020-2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2020-2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc.